From: BRCA2 carriers with male breast cancer show elevated tumour methylation
Feature | ||
---|---|---|
Age (years) | Median = 62.5 | Range: 30–85 |
Mutation carrier status | ||
  BRCA1 | 3 | 5.0% |
  BRCA2 | 25 | 41.7% |
  BRCAX | 32 | 53.3% |
Size (mm) | Median = 17 | Range: 2–50 |
Histological subtype | ||
 Invasive carcinoma - no special type (IC-NST) | 46 | 76.7% |
 Invasive papillary carcinoma | 8 | 13.3% |
 IC-NST with areas of micropapillary | 4 | 6.7% |
 Invasive lobular carcinoma | 2 | 3.3% |
Grade | ||
 1 | 2 | 3.3% |
 2 | 30 | 50.0% |
 3 | 28 | 46.7% |
DCIS | ||
 Present | 41 | 68.3% |
 Absent | 15 | 25.0% |
 Unknown | 4 | 6.7% |
Nodal Status | ||
 N0 | 28 | 46.7% |
 N1 | 20 | 33.3% |
 Nx | 12 | 20.0% |
Paget’s Disease | ||
 Present | 8 | 13.3% |
 Absent | 44 | 73.3% |
 Unknown | 8 | 13.3% |
ER status (Allred score) | Â | Â |
 Negative (0–4/8) | 2 | 3.3% |
 Positive (5–8/8) | 58 | 96.7% |
PgR status (allred score) | ||
 Negative (0–4/8) | 8 | 13.3% |
 Positive (5–8/8) | 52 | 86.7% |
HER2 (SISH) | ||
 Amplified | 5 | 8.3% |
 Non-amplified | 55 | 91.7% |
Phenotype | ||
 Luminal | 54 | 90.0% |
 HER2 | 5 | 8.3% |
 Basal | 1 | 1.7% |